Covid Pandemic Controversy: Antibody Treatment Success Is Disputed

Covid Pandemic Controversy: Antibody Treatment Success Is Disputed
SHARE

Experts all over the world are still struggling to battle the novel coronavirus and the terrible disease that it can trigger. 

Just the other day, we were revealing that there are all kinds of reports surrounding the covid vaccines and especially their potential side effects. AstraZeneca is making headlines these days due to various reasons.

 ABC.net.au just noted that the AstraZeneca vaccine will now be called Vaxzevria after an application to rename it was approved by Australia’s medical regulator.

It’s also been reported that the company asked the Therapeutic Goods Administration (TGA) to approve the rebrand – it said that it would bring the name into line with what the vaccine is called in European countries and Canada.

More than that, AstraZeneca said on Friday its antibody therapy met the main goal of preventing COVID-19 disease in a late-stage study.

Antibody treatments’ results are debated 

CNN just reported that Texas GOv. Greg Abbott revealed during this week, and he tested positive for Covid 19. An important thing that is worth mentioning is that he was treated with a therapy that has not been approved by the FDA yet – monoclonal antibodies. 

“Monoclonal antibodies such as those made by Regeneron and GlaxoSmithKline won’t work for every Covid-19 patient; mAbs, as they are known, are only available for people age 12 and older and who aren’t hospitalized or severely ill,” according to official notes revealed by CNN. 

It’s also worth highlighting the fact that Regeneron’s therapy can also be used for some people who know they were exposed to the virus but don’t yet have a positive test.

Source: Pixabay
Source: Pixabay

On the other hand, it’s essential to learn that protection doesn’t last long, and it’s not a replacement for the vaccine, according to expert opinions on the matter. 

Anyway, the treatments have been proven effective at reducing severe disease. 


SHARE
Rada Mateescu

Passionate about subjects from the science and health-related areas, Rada has been blogging for about ten years and at Health Thoroughfare, she's covering the latest news on these niches.

Post Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.